Updated: Aug 27, 2020
LAS VEGAS - August 26, 2020 - Jesse John Francis Clark, Founder of HemoAware, launches biotechnology company to develop a cure for Hemophilia and other inherited bleeding disorders. Fixx Pharmaceuticals Inc. is a new biotechnology company launching on September 1, 2020. The company is focused on developing therapies specifically targeted to treat patients suffering from bleeding disorders with the use of CRISPR gene editing.
Clark resigned as President & CEO of HemoAware back in January to launch a Fixx Pharmaceuticals. "I'm here to disrupt the market." says Clark. "The hemophilia community has suffered long enough. There are many challenges for people with hemophilia, the most common of which are joint bleeds and deformity, which affect the quality of life for many of us. When we do develop a cure, we will help patients in developing countries first. For example, India has a high patient load of over 18,000 and less than 20% have insurance.”
Currently, there are 20,000 people in the U.S. who suffer from hemophilia and 400,000 globally. The hemophilia market size is valued at over 11 billion.
For more information about Fixx Pharmaceuticals Inc., please visit http://www.fixxpharma.com.
About the Company
Fixx Pharmaceuticals’ mission is to develop targeted therapies to support patients suffering from bleeding disorders, specifically Hemophilia. The company was founded in 2020 and is located in Las Vegas and California.